|Other Names||Plasma kallikrein, Fletcher factor, Kininogenin, Plasma prekallikrein, Plasma kallikrein heavy chain, Plasma kallikrein light chain, KLKB1, KLK3|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP14109b was selected from the C-term region of KLKB1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Plasma prekallikrein is a glycoprotein that participatesin the surface-dependent activation of blood coagulation,fibrinolysis, kinin generation and inflammation. It is synthesizedin the liver and secreted into the blood as a single polypeptidechain. Plasma prekallikrein is converted to plasma kallikrein byfactor XIIa by the cleavage of an internal Arg-Ile bond. Plasmakallikrein therefore is composed of a heavy chain and a light chainheld together by a disulphide bond. The heavy chain originatesfrom the amino-terminal end of the zymogen and contains 4 tandemrepeats of 90 or 91 amino acids. Each repeat harbors a novelstructure called the apple domain. The heavy chain is required forthe surface-dependent pro-coagulant activity of plasma kallikrein.The light chain contains the active site or catalytic domain of theenzyme and is homologous to the trypsin family of serine proteases.Plasma prekallikrein deficiency causes a prolonged activatedpartial thromboplastin time in patients.
MacKenzie, J.A., et al. Appl Physiol Nutr Metab 35(4):518-525(2010)Han, S., et al. Hum. Immunol. 71(7):727-730(2010)Rajaraman, P., et al. Cancer Epidemiol. Biomarkers Prev. 19(5):1356-1361(2010)Eeckhoudt, S.L., et al. Thromb. Haemost. 103(4):866-867(2010)Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.